The Federal Council of Medicine (CFM) banned the medical use of PMMA-based (polymethyl methacrylate) products as injectable substance for dermal filling or soft tissue augmentation throughout Brazil. The determination, applicable to both aesthetic and reconstructive purposes, is recorded in Resolution CFM No. 2,461/2026.
The regulation provides an exception for treating facial and body lipodystrophy in patients living with HIV/AIDS. In such cases, PMMA use is permitted exclusively in high-complexity care units accredited by the Unified Health System (SUS) and in accordance with protocols established by the Ministry of Health.
CFM supported the resolution by compiling scientific evidence linking PMMA use as an injectable filler to several complications. These include late inflammatory reactions, granuloma formation, infections, necrosis, hypercalcemia, and kidney impairment.
The resolution also highlights that some of these complications may manifest long after product application, presenting complex and challenging treatment for affected patients.
